Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients
about
Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's diseaseMonoamine oxidase B inhibitors for early Parkinson's diseaseThe role of oxidative stress in Parkinson's diseaseReview of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.Parkinson's disease.Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.Thematic clustering of text documents using an EM-based approach.Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine AgonistLong-acting versus standard non-ergot dopamine agonists in Parkinson's disease: a meta-analysis of randomized controlled trials.Present and future drug treatment for Parkinson's disease.A comprehensive approach to Parkinson's disease. How to manage fluctuating motor and nonmotor symptoms.Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc AnalysisProgress in neuroprotection in Parkinson's disease.Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life StudyComparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.How should we treat a patient with early Parkinson's disease?Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.Treatment in early Parkinson's disease: the Norwegian ParkWest study.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.The management of orthostatic hypotension in Parkinson's disease.Early versus delayed initiation of pharmacotherapy in Parkinson's disease.Improving L-dopa therapy: the development of enzyme inhibitors.A Small-Molecule Probe for Selective Profiling and Imaging of Monoamine Oxidase B Activities in Models of Parkinson's Disease.Using monoamine oxidase type B inhibitors in Parkinson's disease.Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.Inhibitory effects of curcumin and cyclocurcumin in 1-methyl-4-phenylpyridinium (MPP+) induced neurotoxicity in differentiated PC12 cells.Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?A sensitive two-photon probe to selectively detect monoamine oxidase B activity in Parkinson's disease models.Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis.Early (Uncomplicated) Parkinson's Disease
P2860
Q24240186-43BFA4F4-43BA-4258-9805-1A8B687454C2Q24246514-329279EB-B8C4-428B-8540-0517F6D0E091Q24307946-B4548B45-DF1D-409B-97C0-217AF06EC1E4Q33260250-152C6573-DD8D-4D35-977A-77C054073CB8Q33448272-395958D2-0C8A-497C-ADB1-A915C7B234A5Q34027880-05D50F84-A519-4DB6-A72F-834FFE4C4161Q34436702-2134C9C9-CF3E-4C17-979E-0EE7A182D455Q34504316-CE8FD378-5EBB-40F5-9E37-0459E7080205Q35109436-0460336F-8D2B-4D37-86AA-9C0EBDED9946Q35484805-54569563-A368-46F3-B7E5-6ECF5A5DA92FQ36567733-2B73EB5C-47F9-44F8-8FF7-AC35D1C563F1Q37053860-3E278BD9-5AE5-4994-BC09-AAD7E11BAE28Q37114112-62D2AFC1-3B05-4B37-B9F1-270269E4C669Q37265848-470EDDC5-E4F4-40B1-9C0C-E60C88ED5004Q37736512-58E3D24B-8447-4387-89E6-18800C57B88EQ37775098-20789217-B061-4C23-996F-8196D0718A35Q37865446-E2C4F12E-BADC-495A-A466-D09C63D4A5C1Q37963572-5B2A91FB-637B-41E4-8591-8792F54D4F79Q38063341-4514ADF0-21A9-4253-A0B6-C47C636C3E2BQ38070888-C3FBBB84-1D8B-4FD2-B8B1-F994CBB01FD2Q38112214-3104B43B-AE60-4290-99C5-B40D407E8265Q38114882-B9A14FB9-D234-4DC9-87A6-271698A63B7CQ38206403-103902DC-BF4E-4594-9B0A-E282D5600D4DQ38261811-9C681DC0-037B-4D72-B397-AB1A6D6C3370Q38849922-E01D9C2F-2399-4380-A5CD-C2282AC6C7C4Q42395722-00270233-BA0B-4849-A989-042769FE227BQ42705333-90E67FF6-58BC-43FB-9D07-B39A3A57AF8BQ46247320-ED27F722-EC62-4EB9-903A-826EFEEE274CQ46823146-96618B5F-9BBC-448C-AB11-951632327DD4Q52766051-55757BB8-3BBB-4E22-9DF5-1686B448C467Q54099574-76308EE7-6F61-435E-95B2-4C696C1BBB3EQ58870319-B09D7A85-CD3C-4BD8-BDC2-09F3A7A06BCF
P2860
Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Monoamine oxidase type B inhib ...... trials involving 3525 patients
@ast
Monoamine oxidase type B inhib ...... trials involving 3525 patients
@en
Monoamine oxidase type B inhib ...... trials involving 3525 patients
@nl
type
label
Monoamine oxidase type B inhib ...... trials involving 3525 patients
@ast
Monoamine oxidase type B inhib ...... trials involving 3525 patients
@en
Monoamine oxidase type B inhib ...... trials involving 3525 patients
@nl
prefLabel
Monoamine oxidase type B inhib ...... trials involving 3525 patients
@ast
Monoamine oxidase type B inhib ...... trials involving 3525 patients
@en
Monoamine oxidase type B inhib ...... trials involving 3525 patients
@nl
P2093
P2860
P50
P921
P3181
P1433
P1476
Monoamine oxidase type B inhib ...... trials involving 3525 patients
@en
P2093
Angus Macleod
Carl Counsell
Joanna Marro
Keith Wheatley
Natalie J Ives
P2860
P3181
P356
10.1136/BMJ.38184.606169.AE
P407
P577
2004-08-13T00:00:00Z